RxDoctor Payments Data

Sunil Tulpule, MD

Hematology & Oncology · Phoenix, AZNPI 1366988024

Payments from drug & device makers

$36,455in general payments, 2019–2025

Across 84 payments — averaging $433.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ADC Therapeutics America, Inc.$19K
  • Sanofi$6K
  • Syndax Pharmaceuticals, Inc.$4K
  • Kyowa Kirin, Inc.$3K
  • Genmab U.S., Inc.$2K
  • AbbVie$603
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$17,03247%
  • Speaking & faculty fees$12,70035%
  • Travel & lodging$1,3324%
  • Food & beverage$5,08514%
  • Education$3061%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,455 in reported general payments places this provider in the 50th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$58,567
Medicare patients
175
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide54$646,883
VenclextaVenetoclax56$552,309
OjjaaraMomelotinib Dihydrochloride12$332,778
BrukinsaZanubrutinib24$330,864
JakafiRuxolitinib Phosphate15$278,541
CalquenceAcalabrutinib Maleate12$179,263
EliquisApixaban15$16,900
Deferasirox11$14,674
Enoxaparin Sodium15$5,873
ValacyclovirValacyclovir Hcl58$2,348
Ondansetron Hcl62$1,227
Fluconazole31$1,159
Hydroxyurea39$772
Gabapentin14$741
Prochlorperazine Maleate37$707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$603$552,30956 claims
AstraZenecaCalquence$253$179,26312 claims
PfizerEliquis$106$16,90015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 261 hematology & oncology providers in Arizona.

Other hematology & oncology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →